96 related articles for article (PubMed ID: 28732393)
1. MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
Zhou K; Luo X; Wang Y; Cao D; Sun G
Biomed Pharmacother; 2017 Sep; 93():1025-1032. PubMed ID: 28732393
[TBL] [Abstract][Full Text] [Related]
2. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells.
Liu P; Wilson MJ
J Cell Physiol; 2012 Feb; 227(2):867-76. PubMed ID: 21898400
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Wang S; Zhang X; Wang G; Cao B; Yang H; Jin L; Cui M; Mao Y
BMC Cancer; 2019 Nov; 19(1):1160. PubMed ID: 31783811
[TBL] [Abstract][Full Text] [Related]
4. UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.
Sun J; Wu K; Chen S; Jiang S; Chen Y; Duan C
Int J Med Sci; 2021; 18(14):3097-3105. PubMed ID: 34400880
[TBL] [Abstract][Full Text] [Related]
5. RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.
Zhou J; Tu D; Peng R; Tang Y; Deng Q; Su B; Wang S; Tang H; Jin S; Jiang G; Wang Q; Jin X; Zhang C; Cao J; Bai D
Cell Commun Signal; 2023 Aug; 21(1):224. PubMed ID: 37626338
[TBL] [Abstract][Full Text] [Related]
6. miR-451a suppresses the proliferation and migration of high-grade serous ovarian cancer by targeting RAB5A through the Ras/Raf/MEK/ERK pathway.
Liu S; Wang K; Zhao Z; Pang Y; Liu F; Wang P; Wang Z; Yang X
J Gene Med; 2024 Jan; 26(1):e3649. PubMed ID: 38282155
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis.
Huang WT; Chen ZX; He RQ; Wu YZ; Yin SY; Liang XN; Chen G; Yang H; Peng ZG; Yang LH
Onco Targets Ther; 2016; 9():5061-71. PubMed ID: 27574447
[TBL] [Abstract][Full Text] [Related]
8. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
9. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X
Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642
[TBL] [Abstract][Full Text] [Related]
10. MiR-30a-5p inhibits proliferation and metastasis of hydatidiform mole by regulating B3GNT5 through ERK/AKT pathways.
Guo Z; Sun Q; Liao Y; Liu C; Zhao W; Li X; Liu H; Dong M; Shang Y; Sui L; Kong Y
J Cell Mol Med; 2020 Aug; 24(15):8350-8362. PubMed ID: 32575164
[TBL] [Abstract][Full Text] [Related]
11. MiR-760 inhibits the progression of non-small cell lung cancer through blocking ROS1/Ras/Raf/MEK/ERK pathway.
Wang W; He B
Biosci Rep; 2020 Apr; ():. PubMed ID: 32347292
[TBL] [Abstract][Full Text] [Related]
12. Human MiR-544a Modulates SELK Expression in Hepatocarcinoma Cell Lines.
Potenza N; Castiello F; Panella M; Colonna G; Ciliberto G; Russo A; Costantini S
PLoS One; 2016; 11(6):e0156908. PubMed ID: 27275761
[TBL] [Abstract][Full Text] [Related]
13. Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK Signaling.
Shah AD; Bouchard MJ; Shieh AC
PLoS One; 2015; 10(11):e0142337. PubMed ID: 26560447
[TBL] [Abstract][Full Text] [Related]
14.
Wang K; Chu Y; Zhang H; Qu X; Wang B; Han Y
Comb Chem High Throughput Screen; 2024; 27(3):436-445. PubMed ID: 37151068
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9.
Jiang L; Liu Y; Ma C; Li B
Oncol Lett; 2018 Sep; 16(3):3038-3044. PubMed ID: 30127894
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.
Zhao J; Li B; Shu C; Ma Y; Gong Y
Oncol Lett; 2017 Dec; 14(6):7437-7442. PubMed ID: 29344185
[TBL] [Abstract][Full Text] [Related]
17. Interaction between miR‑206 and lncRNA MALAT1 in regulating viability and invasion in hepatocellular carcinoma.
Wang J; Yao G; Zhang B; Zhao Z; Fan Y
Oncol Lett; 2024 Jan; 27(1):5. PubMed ID: 38028177
[TBL] [Abstract][Full Text] [Related]
18. Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis.
Klemm S; Evert K; Utpatel K; Muggli A; Simile MM; Chen X; Evert M; Calvisi DF; Scheiter A
BMC Cancer; 2023 Nov; 23(1):1086. PubMed ID: 37946160
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of MiR-365 as a novel indicator to assess the progression and metastasis of hepatocellular carcinoma.
He RQ; Pang YY; Zhang R; Liang HW; Li CY; Ma J; Feng ZB; Peng ZG; Chen G
Int J Clin Exp Pathol; 2017; 10(9):9164-9176. PubMed ID: 31966789
[TBL] [Abstract][Full Text] [Related]
20. The miR-34b/MEK/ERK pathway is regulated by NR5A1 and promotes differentiation in primary bovine Sertoli cells.
Tao Q; Zhang L; Zhang Y; Liu M; Wang J; Zhang Q; Wu J; Wang A; Jin Y; Tang K
Theriogenology; 2024 Feb; 215():224-233. PubMed ID: 38100994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
